4D Molecular Therapeutics Inc (FDMT) 뉴스

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet...

4DMT Announces Presentations at Upcoming Retina Conferences

EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet...

Form 4 - Statement of changes in beneficial ownership of securities